Australia - English - Department of Health (Therapeutic Goods Administration)

bioflex nutrition pty ltd - resveratrol, quantity: 150 mg - capsule, hard - excipient ingredients: hypromellose; purified water; silicon dioxide - antioxidant/reduce free radicals formed in the body

Australia - English - Department of Health (Therapeutic Goods Administration)

bioflex nutrition pty ltd - magnesium amino acid chelate, quantity: 500 mg (equivalent: magnesium, qty 100 mg); pyridoxine hydrochloride, quantity: 10 mg (equivalent: pyridoxine, qty 8.23 mg); zinc amino acid chelate, quantity: 30 mg (equivalent: zinc, qty 6 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; hypromellose; purified water - maintain/support body electrolyte balance ; maintain/support healthy immune system function ; maintain/support muscle function ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support healthy sleeping patterns ; helps maintain/support testosterone formation/synthesis ; maintain/support testosterone level

Australia - English - Department of Health (Therapeutic Goods Administration)

bioflex nutrition pty ltd - glucosamine sulfate potassium chloride, quantity: 150 mg (equivalent: glucosamine, qty 88.8 mg; equivalent: potassium chloride, qty 18.465 mg); shark chondroitin sulfate, quantity: 55.56 mg (equivalent: chondroitin sulfate, qty 50 mg); dimethyl sulfone, quantity: 200 mg; ascorbic acid, quantity: 25 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; purified water; microcrystalline cellulose; magnesium stearate; hypromellose - antioxidant/reduce free radicals formed in the body ; maintain/support collagen formation ; maintain/support energy production ; maintain/support general health and wellbeing ; maintain/support connective tissue health ; aid/assist/helps connective tissue production/formation ; maintain/support bone health ; helps maintain/support joint cartilage health ; maintain/support joint health ; maintain/support wound healing ; maintain/support skin repair/healing/regeneration

Australia - English - Department of Health (Therapeutic Goods Administration)

bioflex nutrition pty ltd - citrus aurantium, quantity: 20 mg (equivalent: citrus aurantium, qty 500 mg; equivalent: oxedrine, qty 2.4 mg); caffeine, quantity: 80 mg; camellia sinensis, quantity: 470 mg (equivalent: camellia sinensis, qty 14.1 g; equivalent: caffeine, qty 2.35 mg); chromium picolinate, quantity: 198 microgram (equivalent: chromium, qty 25 microgram) - capsule, hard - excipient ingredients: purified water; hypromellose; silicon dioxide - antioxidant/reduce free radicals formed in the body ; helps maintain/support healthy blood sugar/glucose ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; enhance/improve/promote/increase mental alertness/wakefulness

Australia - English - Department of Health (Therapeutic Goods Administration)

tamaree holdings pty atf tamaree holdings trust - 35519 - traction unit, non-active - the bioflex is intended to aid in the natural traction of the body.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - acetazolamide 250mg;   - tablet - 250 mg - active: acetazolamide 250mg   excipient: calcium hydrogen phosphate dihydrate magnesium stearate povidone sodium starch glycolate starch - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - furosemide 500mg;   - tablet - 500 mg - active: furosemide 500mg   excipient: colloidal silicon dioxide lactose magnesium stearate maize starch maltodextrin - frusemide in a high-dosage formulation such as urex forte (500 mg tablets) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting. high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l/day dialysis has to be used.

New Zealand - English - Medsafe (Medicines Safety Authority)

lumacina new zealand - water for injection 100% - solution for injection - 100 % - active: water for injection 100%

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 11.4mg equivalent to atomoxetine 10 mg - capsule - 10 mg - active: atomoxetine hydrochloride 11.4mg equivalent to atomoxetine 10 mg excipient: gelatin   starch tekprint black sw-9008 tekprint black sw-9009 titanium dioxide   water   - indicated for the treatment of attention deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 114mg equivalent to atomoxetine 100 mg - capsule - 100 mg - active: atomoxetine hydrochloride 114mg equivalent to atomoxetine 100 mg excipient: gelatin   iron oxide red   iron oxide yellow   starch tekprint black sw-9008 tekprint black sw-9009 titanium dioxide   water   - indicated for the treatment of attention deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.